Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
28 Février 2024 - 2:00PM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage
oncology company developing MasterKey therapies that target
families of oncogenic mutations in patients with genetically
defined cancers, today announced that its Chief Executive Officer,
Mark A. Velleca, M.D., Ph.D., will participate in a panel
discussion on lung cancer at the TD Cowen 44th Annual Health Care
Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET in Boston,
MA.
A live webcast of the panel can be accessed by
visiting the investor relations section of the Company’s website
at: www.blackdiamondtherapeutics.com. A replay of the webcast will
also be available and archived for 90 days following the event.
About Black DiamondBlack
Diamond Therapeutics is a clinical-stage oncology company focused
on the development of MasterKey therapies that address families of
oncogenic mutations in clinically validated targets. The Company’s
MasterKey therapies are designed to address broad genetically
defined patient populations, overcome resistance, minimize
wild-type mediated toxicities, and be brain penetrant to treat CNS
disease. The Company is advancing two clinical-stage programs:
BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey
inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a
brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and
BRAF alterations in solid tumors. For more information, please
visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:Mario Corso, Head of Investor Relations, Black
Diamond Therapeuticsmcorso@bdtx.com
For Media:media@bdtx.com
Black Diamond Therapeutics (NASDAQ:BDTX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024